4.7 Review

Intensive management of obesity in people with severe chronic kidney disease: A review

期刊

DIABETES OBESITY & METABOLISM
卷 23, 期 8, 页码 1733-1745

出版社

WILEY
DOI: 10.1111/dom.14409

关键词

bariatric surgery; end‐ stage kidney disease; obesity; obesity pharmacotherapy; VLEDs; weight loss

向作者/读者索取更多资源

This review evaluated the safety of intensive obesity treatments in people with end-stage kidney disease, finding limited data on very-low-energy diets but highlighting their potential efficacy and the need for close monitoring. Central acting obesity pharmacotherapy and bariatric surgery in this population raised safety concerns, requiring further investigation.
Obesity is highly prevalent worldwide, including among people with chronic kidney disease (CKD). The presence of severe and/or end-stage kidney disease complicates the treatment of obesity for several reasons, including restrictions on protein and fluid intake and renal excretion of several medications indicated for the treatment of obesity. The aim of this review is to assess the safety of intensive obesity treatments, such as very-low-energy diets (VLEDs), obesity pharmacotherapy and/or bariatric surgery, in people with end-stage kidney disease. A literature search was conducted to identify studies reporting safety outcomes for VLEDs, liraglutide, phentermine, phentermine-topiramate, naltrexone-bupropion and bariatric surgery in people with an estimated glomerular filtration rate of less than 30 mL/min/1.73m(2) or on dialysis. Limited data were insufficient to recommend VLEDs but highlighted their potential efficacy and the need for close clinical and biochemical monitoring. There were no data regarding centrally acting obesity pharmacotherapy in this population, although some glucagon-like peptide-1 analogues appear to safely induce weight loss at doses used for the treatment of type 2 diabetes. Some studies suggest an increased rate of complications of bariatric surgery in individuals with severe or end-stage CKD. Further prospective evaluation of intensive obesity management in the growing population with obesity and severe, end-stage and dialysis-dependent CKD is required.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据